Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care

To determine the feasibility of universal genetic testing of women with newly diagnosed breast cancer, to estimate the incidence of pathogenic gene variants and their impact on patient management, and to evaluate patient and clinician acceptance of universal testing.

• Publication year

  2023

• Venue

  Medical Journal of Australia

• Publication date

  2023-04-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.5694/mja2.51906PMID 37005005PMCID 10952347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer

  2022cited by this paper
• Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

  2021cited by this paper
• Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre

  2021cited by this paper
• The ten genes for breast (and ovarian) cancer susceptibility

  2021cited by this paper
• A Population-Based Study of Genes Previously Implicated in Breast Cancer.

  2021cited by this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cited by this paper
• Universal genetic testing of patients with newly diagnosed breast cancer — ready for prime time?

  2021cited by this paper
• Mainstream consent programs for genetic counseling in cancer patients: A systematic review

  2020cited by this paper
• CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants

  2020cited by this paper
• Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer

  2019cited by this paper
• Breast cancer

  2019cited by this paper
• A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

  2019cited by this paper
• Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

  2018cited by this paper
• Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history

  2018cited by this paper
• Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark

  2018cited by this paper
• Medicare‐funded cancer genetic tests: a note of caution

  2018cited by this paper
• Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing

  2018cited by this paper
• Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial

  2016cited by this paper
• KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy

  2015cited by this paper
• The Concerns About Recurrence Questionnaire: validation of a brief measure of fear of cancer recurrence amongst Danish and Australian breast cancer survivors

  2015cited by this paper
• Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer

  2014cited by this paper
• Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing

  2009cited by this paper
• Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support

  2009cited by this paper
• Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics

  2008cited by this paper
• Validation of a Decision Regret Scale

  2003cited by this paper
• The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories.

  1995cited by this paper

• Universal vs. ASCO guidelines-based germline genetic testing for newly diagnosed breast cancer patients in resource-restricted settings

  2026cites this paper
• Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles

  2026cites this paper
• Recent advances in non-pharmacological interventions for symptom burden management in breast cancer patients treated with ovarian function suppression

  2026cites this paper
• Quality of life, anxiety and cancer worry following hereditary cancer testing: a 6-month Swedish follow-up study

  2026cites this paper
• Integrating breast tumor homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification

  2025cites this paper
• The association of race and ethnicity with risk-reducing mastectomies in patients with non-BRCA mutations.

  2025cites this paper
• Genetic testing in cancer: a systematic review of patient reported measures

  2025cites this paper
• Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.

  2025cites this paper
• A Systematic Review of Patient-Reported Measures for Individuals Who Underwent Genetic Testing for Heritable Cancer

  2025cites this paper
• Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of BRCA1 or BRCA2 Pathogenic Variants

  2025cites this paper
• Short-term Patient-Reported Outcomes Following Bilateral Risk-Reducing Mastectomy for Patients at a High Risk for Breast Cancer: A Systematic Review

  2025cites this paper
• Uptake and patient-related outcomes of mainstreaming genetic testing - a systematic review and meta-analysis.

  2025cites this paper
• Reduced Breast and Ovarian Cancer Through Targeted Genetic Testing: Estimates Using the NEEMO Microsimulation Model

  2024cites this paper
• Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review

  2024cites this paper
• BRCA testing and management of BRCA-mutated early-stage breast cancer: a comprehensive statement by expert group from GCC region

  2024cites this paper
• MAGENTA: a Multinational patient survey assessing the Awareness, perceptions and unmet needs in GENetic Testing and counselling among patients with breAst cancer

  2024cites this paper
• Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia

  2024cites this paper
• Screening guidelines for people at increased risk for prostate cancer.

  2024cites this paper
• Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer

  2024cites this paper
• Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer

  2024cites this paper
• Clinical, histological and receptor profiles of invasive breast cancer and ductal carcinoma in situ in females with germline pathogenic variants in PTEN and implications for germline testing.

  2024cites this paper
• Establishment of a clinical cancer genetics program for breast cancer in a resource-limited country; challenges and opportunities

  2024cites this paper
• Moving breast cancer susceptibility gene testing into the mainstream

  2023cites this paper
• Management of breast cancer patients with BRCA gene mutations in Jordan: perspectives and challenges

  2023cites this paper
• Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making

  2023cites this paper
• Capacity building and development trends of the multidisciplinary integrated treatment model for breast cancer

  year unknowncites this paper